Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6LS4

A novel anti-tumor agent S-40 in complex with tubulin

Summary for 6LS4
Entry DOI10.2210/pdb6ls4/pdb
DescriptorTubulin alpha-1B chain, Tubulin beta chain, Stathmin, ... (10 entities in total)
Functional Keywordsmitosis, antitumor protein, structural protein
Biological sourceSus scrofa (Pig)
More
Total number of polymer chains5
Total formula weight221758.00
Authors
Du, T.,Lin, S.,Ji, M.,Xue, N.,Liu, Y.,Zhang, K.,Lu, D.,Chen, X.,Xu, H. (deposition date: 2020-01-17, release date: 2021-01-20, Last modification date: 2023-11-29)
Primary citationDu, T.,Lin, S.,Ji, M.,Xue, N.,Liu, Y.,Zhang, Z.,Zhang, K.,Zhang, J.,Zhang, Y.,Wang, Q.,Sheng, L.,Li, Y.,Lu, D.,Chen, X.,Xu, H.
A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Cancer Lett., 495:22-32, 2020
Cited by
PubMed Abstract: The tubulin colchicine binding site has been recognized as an attractive drug target to combat cancer, but none of the candidate drugs have been approved for medical treatment. We recently identified a structurally distinct small molecule S-40 as an oral potent tubulin destabilizing agent. Crystal structure analysis of S-40 in a complex with tubulin at a resolution of 2.4 Å indicated that S-40 occupies all 3 zones in the colchicine pocket with interactions different from known microtubule inhibitors, presenting unique effects on assembly and curvature of tubulin dimers. S-40 overcomes paclitaxel resistance and lacks neurotoxicity, which are the main obstacles limiting clinical applications of paclitaxel. Moreover, S-40 harbors the ability to inhibit growth of cancer cell lines as well as patient-derived organoids, induce mitotic arrest and cell apoptosis. Xenograft mouse models of human prostate cancer DU145, non-small cell lung cancer NCI-H1299 and paclitaxel-resistant A549 were strongly restrained without apparent side effects by S-40 oral administration once daily. These findings provide evidence for the development of S-40 as the next generation of orally effective microtubule inhibitors for cancer therapy.
PubMed: 32931884
DOI: 10.1016/j.canlet.2020.08.040
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon